Article
Rheumatology
Renske C. F. Hebing, Marry Lin, Maja Bulatovic Calasan, Ittai B. Muller, Sohaila Mahmoud, Sandra Heil, Eduard A. Struys, Bart J. F. van den Bemt, Jos W. R. Twisk, Willem Lems, Michael T. Nurmohamed, Gerrit Jansen, Robert de Jonge
Summary: This study investigates the pharmacokinetics of methotrexate polyglutamate (MTX-PG) accumulation in red blood cells (RBCs) and peripheral blood mononuclear cells (PBMCs) in patients with early rheumatoid arthritis (RA) after oral and subcutaneous MTX treatment. The results show that there are disparate pharmacokinetic profiles between PBMCs and RBCs, with higher accumulation of MTX-PG in PBMCs. The distribution profile of MTX-PG in PBMCs remains constant over 6 months, while in RBCs, the main PG-moiety changes from MTX-PG(1) to MTX-PG(3).
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Paul Studenic, Daniel Aletaha, Maarten de Wit, Tanja A. Stamm, Farideh Alasti, Diane Lacaille, Josef S. Smolen, David T. Felson
Summary: This study aimed to externally validate a revised Boolean remission criteria using a higher patient global assessment (PtGA) threshold and validate the provisionally endorsed index-based criteria. The results showed that using the higher PtGA threshold increased the proportion of patients classified as achieving remission under the "Boolean2.0" criteria, improved agreement with index-based criteria, and did not compromise predictive value for radiographic or functional outcomes. The study findings were endorsed by ACR and EULAR.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Janne Heuvelmans, Nathan den Broeder, Geke A. H. van den Elsen, Alfons A. den Broeder, Bart J. F. van den Bemt
Summary: This study aimed to compare the effectiveness and tolerability of oral MTX and s.c. MTX in RA patients. The results showed that oral MTX was non-inferior to s.c. MTX in terms of disease activity control, with a slightly lower dose and better tolerability.
Article
Rheumatology
Delila Singh, Nina Hesse, Alla Skapenko, Hendrik Schulze-Koops
Summary: Methotrexate is associated with rare bone lesions that are often misdiagnosed as osteoporotic fractures. Early diagnosis is crucial for treatment and prevention of further osteopathology. This case highlights the importance of raising awareness and taking appropriate therapeutic measures, including discontinuing methotrexate.
Article
Chemistry, Analytical
Junqing He, Junyan Wang, Min Zhang, Guoyue Shi
Summary: As a folate antagonist, methotrexate (MTX) has been widely used in clinics for treating various tumors and inflammatory diseases. However, the dosage and clearance of MTX vary between individuals, and it may cause life-threatening side effects at high doses. Therefore, a convenient and simple method for MTX sensing is highly demanded.
Article
Chemistry, Multidisciplinary
Parvathy Suresh, Mounir M. Salem-Bekhit, Hafsa Palathum Veedu, Sultan Alshehri, Sreeja Chandrasekhar Nair, Sarah Bukhari, Vidya Viswanad, Ehab Taha, Ram Kumar Sahu, Mohammed M. Ghoneim, Ibrahim Elbagory
Summary: A novel formulation of methotrexate-loaded nanoemulsion was developed to deliver methotrexate into the system via the lymph for the treatment of rheumatoid arthritis. The optimized nanoemulsion showed excellent physicochemical properties, significant anti-arthritic activity, and stability when stored at a low temperature.
Article
Rheumatology
Clement Triaille, Gaelle Tilman, Tatiana Sokolova, Axelle Loriot, Joelle Marchandise, Stephanie De Montjoye, Adrien Nzeusseu-Toukap, Laurent Meric de Bellefon, Caroline Bouzin, Christine Galant, Patrick Durez, Bernard R. Lauwerys, Nisha Limaye
Summary: This study used transcriptomic profiling to explore clinically relevant subgroups in early, untreated rheumatoid arthritis (RA) patients. The synovial transcriptome closely mirrored clinical disease activity, and the ratio of M2:M1 macrophages was inversely correlated with inflammation and disease activity, suggesting a protective role for tissue resident macrophages in RA.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Claire Daien, Marek Krogulec, Paul Gineste, Jean-Marc Steens, Laurence Desroys du Roure, Sophie Biguenet, Didier Scherrer, Julien Santo, Hartmut Ehrlich, Patrick Durez
Summary: This study evaluated the safety and efficacy of ABX464 in patients with moderate-to-severe active rheumatoid arthritis. The results showed that ABX464 at a 50 mg dose was safe, well tolerated, and showed promising efficacy. The 100 mg dose had a high dropout rate due to gastrointestinal adverse events.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Siddharth Jain, Varun Dhir, Amita Aggarwal, Ranjan Gupta, Bidyalaxmi Leishangthem, Shankar Naidu, Aastha Khullar, Supriya Maurya, Veena Dhawan, Shefali Khanna Sharma, Aman Sharma, Sanjay Jain
Summary: This study compared the efficacy and safety of different dose escalation strategies of oral MTX in RA patients over a period of 16-24 weeks. The results showed that a faster escalation strategy was not more effective than the usual strategy, but was associated with higher gastrointestinal adverse events in the initial phase.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Multidisciplinary Sciences
Helen R. Gosselt, Costanza L. Vallerga, Pooja R. Mandaviya, Erik Lubberts, Johanna M. W. Hazes, Robert de Jonge, Sandra G. Heil
Summary: The study did not identify genome-wide significant differences as biomarkers for Methotrexate (MTX) therapy response, necessitating meta-analyses.
Article
Rheumatology
Ulf Lindstrom, Daniela di Giuseppe, Sofia Exarchou, Gerd-Marie Alenius, Tor Olofsson, Eva Klingberg, Lennart Jacobsson, Johan Askling, Johan K. Wallman
Summary: This study aimed to compare the treatment outcomes of patients with newly diagnosed psoriatic arthritis (PsA) and rheumatoid arthritis (RA) using methotrexate (MTX) monotherapy. The results showed that PsA patients were less likely to continue the use of MTX compared to RA patients, and the effectiveness of MTX was also lower in PsA.
Review
Pharmacology & Pharmacy
Gurleen Kour, Syed Assim Haq, Bijender Kumar Bajaj, Prem N. Gupta, Zabeer Ahmed
Summary: Phytochemicals have long been known for their therapeutic potential in autoimmune disorders such as rheumatoid arthritis, but their combination with DMARDs can increase the efficacy of treatment while reducing toxic side effects. Studies have shown promising results in experimental and clinical settings when combining phytochemicals with DMARDs, highlighting the importance of this approach in future RA therapy.
PHARMACOLOGICAL RESEARCH
(2021)
Review
Endocrinology & Metabolism
F. Robin, S. Cadiou, J-D Albert, G. Bart, G. Coiffier, P. Guggenbuhl
Summary: Methotrexate (MTX)-related osteopathy, characterized by pain, osteoporosis, and atypical fractures, is a rare condition that has been reported in patients treated with low doses of MTX for inflammatory diseases. Pathophysiological studies suggest a possible dose-dependent residual effect of MTX on osteo-forming bone cells.
OSTEOPOROSIS INTERNATIONAL
(2021)
Article
Immunology
Shu-Lin Chen, Qiang Xu, Chang-Song Lin
Summary: A study found that the therapeutic drugs for rheumatoid arthritis (RA) are associated with thyroid function, with methotrexate being linked to decreased levels of total thyroxine (TT4) and glucocorticoids being linked to decreased levels of total triiodothyronine (TT3).
INFLAMMOPHARMACOLOGY
(2023)
Article
Medicine, Research & Experimental
Marion Geoffroy, Claire Gozalo, Celine Konecki, Loic Pauvele, Ambre Hittinger, Noemie Pastorel, Catherine Feliu, Jean Hugues Salmon, Zoubir Djerada
Summary: This study used population pharmacokinetic modeling to describe the kinetics of urinary methotrexate in treated patients and evaluate its ability to assess methotrexate adherence. The results showed that urinary methotrexate was independently associated with methotrexate administration with high sensitivity and specificity. By developing a pharmacokinetic model and conducting simulations, the proportion of true positive samples can be predicted.
BIOMEDICINE & PHARMACOTHERAPY
(2023)